About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
NCCN Guidelines Update for TNBC and HER2 Breast Cancer: Immunotherapy and PARP Inhibitors in TNBC & Trastuzumab Biosimilars in HER2 BC
By
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
FEATURING
Jame Abraham
,
William Gradishar
September 13, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
17:04
Novartis Oncology
Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…
Feat.
G. Hortobagyi
Featured Video
13:03
Novartis Oncology
CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…
Feat.
D. Slamon
Related Content
AUTOPLAY
ON
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
04:28
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …
Feat.
S. Tolaney
24:36
ESMO 2022 Conference Coverage
ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates
Feat.
H. Rugo,
J. O'Shaughnessy
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
20:42
Total Health
2022 Updates in TNBC
Feat.
I. Schlam
05:45
SABCS 2022 Conference Coverage
SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…
Feat.
S. Tolaney
07:34
PrecisCa
Summary of the Updated Results of SOFT/TEXT Trials and the Meta-Anal…
Feat.
M. Pegram
16:08
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Tailoring Post-Neoadjuvant Therapy in TNB…
Feat.
H. Han
26:28
2023 West Oncology Conference
Antibody Drug Conjugates for Breast Cancer: The End of Chemotherapy?
Feat.
L. Schwartzberg
08:41
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "10-Year Update of the Short-HER Phase III…
Feat.
P. Conte
10:54
Yale Cancer Center
De-Escalation of Adjuvant Therapy in Early Stage HER2+ Breast Cancers
Feat.
L. Pusztai
10:22
ESMO 2022 Conference Coverage
ESMO 2022 Updates on mTNBC
Feat.
L. Carey
07:49
ESMO Breast Cancer 2023 Congress Coverage
ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients…
Feat.
H. Rugo
04:09
ecancer
Management of HER2+ mBC Treatment Algorithm
Feat.
S. Swain
14:11
ESMO Breast Cancer 2023 Congress Coverage
ESMO Breast Cancer 2023 Highlights: Key Studies Including IMPassion0…
Feat.
P. Tarantino
09:24
The University of Kansas Cancer Center
Treatment Sequence in mTNBC
Feat.
P. Sharma
10:06
ecancer
ASCO® 2023 Summary: "Key Studies in Early Breast Cancer"
Feat.
M. Lambertini
12:50
Oncology Data Advisor
Expert Perspectives in the Management of TNBC
Feat.
S. Tolaney
13:17
ASCO 2022 Conference Coverage
ASCO 2022 on EFS by Residual Cancer Burden After Neoadjuvant Pembro …
Feat.
L. Pusztai
29:31
Community Oncology Alliance
Current Advances: Triple Negative & Locally Advanced Breast Canc…
Feat.
E. Hamilton
